Plasma concentrations and therapeutic effects of budesonide in dogs with inflammatory bowel disease

American Journal of Veterinary Research

Volumn 74, Issue 1, 2013, Pages 78-83

  Pietra, Marco ^a   Fracassi, Federico ^a   Diana, Alessia ^a   Gazzotti, Teresa ^a   Bettini, Giuliano ^a   Peli, Angelo ^a   Morini, Maria ^a   Pagliuca, Giampiero ^a   Roncada, Paola ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYPREDNISOLONE; BUDESONIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; DOG; DRUG EFFICACY; ENTERITIS; FEMALE; HISTOLOGY; MALE; NONHUMAN; PROSPECTIVE STUDY; RELATIVE DENSITY; REVERSED PHASE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; URINALYSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CHROMATOGRAPHY, LIQUID; DOG DISEASES; DOGS; FEMALE; GLUCOCORTICOIDS; INFLAMMATORY BOWEL DISEASES; MALE; PREDNISOLONE; TANDEM MASS SPECTROMETRY;

ANIMALIA; CANIS FAMILIARIS;

EID: 84872086131     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.74.1.78     Document Type: Article

References (31)

1. Allenspach K, Wieland B, Gröne A, et al. Chronic enteropathies in dogs: evaluation of risk factors for negative outcome. J Vet Intern Med 2007;21:700-708.
2. Xenoulis PG, Palculict B, Allenspach K, et al. Molecular-phylogenetic characterization of microbial communities imbalances in the small intestine of dogs with inflammatory bowel disease. FEMS Microbiol Ecol 2008;66:579-589.
3. Simpson KW, Jergens AE. Pitfalls and progress in the diagnosis and management of canine inflammatory bowel disease. Vet Clin North Am Small Anim Pract 2011;41:381-398.
4. Washabau RJ, Day MJ, Willard MD, et al. Endoscopic, biopsy, and histopathologic guidelines for the evaluation of gastrointestinal inflammation in companion animals. J Vet Intern Med 2010;24:10-26.
5. Jergens AE. Inflammatory bowel disease. Current perspectives. Vet Clin North Am Small Anim Pract 1999;29:501-521.
6. Willard M, Mansell J. Correlating clinical activity and histopathologic assessment of gastrointestinal lesion severity: current challenges. Vet Clin North Am Small Anim Pract 2011;41:457-463.
7. Guilford WG. Idiopathic inflammatory bowel disease. In: Guilford WG, Center SA, Strombeck DR, et al, eds. Strombeck's small animal gastroenterology. 3rd ed. Philadelphia: WB Saunders Co, 1996;452-453.
8. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003;178:339-346.
9. Edsbäcker S, Andersson P, Lindberg C, et al. Liver metabolism of budesonide in rat, mouse and man. Comparative aspects. Drug Metab Dispos 1987;15:403-411.
10. McKeage K, Goa KL. Budesonide (Entocort® EC capsules). A review of its therapeutic use in the management of active Crohn's disease in adults. Drugs 2002;62:2263-2282.
11. Stroup ST, Behrend EN, Kemppainen RJ, et al. Effects of oral administration of controlled-ileal-release budesonide and assessment of pituitary-adrenocortical axis suppression in clinically normal dogs. Am J Vet Res 2006;67:1173-1178.
12. Spencer CM, McTavish D. Budesonide: a review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995;50:854-872.
13. Jergens AE, Schreiner CA, Frank DE, et al. A scoring index for disease activity in canine inflammatory bowel disease. J Vet Intern Med 2003;17:291-297.
14. Jergens AE. Clinical assessment of disease activity for canine inflammatory bowel disease. J Am Anim Hosp Assoc 2004;40:437-445.
15. Tunek A, Sjödin K, Hallström G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997;25:1311-1317.
16. Wieslander E, Delander EL, Järkelid L, et al. Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line in vitro. Am J Respir Cell Mol Biol 1998;19:477-484.
17. Brattsand R. The ideal steroid. Pulm Pharmacol Ther 1999;12:119-122.
18. Miller-Larsson A, Gustafsson B, Persson CG, et al. Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisone in the rat. Aliment Pharmacol Ther 2001;15:2019-2025.
19. Marín-Jiménez I, Peña AD. Budesonide for ulcerative colitis. Rev Esp Enferm Dig 2006;98:362-373.
20. Zareie M, Brattsand R, Sherman PM, et al. Improved effects of novel glucocorticosteroids on immune-induced epithelial pathophysiology. J Pharmacol Exp Ther 1999;289:1245-1249.
21. Sellin JH, Pasricha PJ. Pharmacotherapy of inflammatory bowel disease. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill Inc, 2006;1014-1015.
22. Woolley MJ, Wattie J, Ellis R, et al. Effect of an inhaled corticosteroid on airway eosinophils and allergen-induced airway hyperresponsiveness in dogs. J Appl Physiol 1994;77:1303-1308.
23. Ahlstrom LA, Mason KV, Mills PC. Barazone decreases skin lesions and pruritus and increases quality of life in dogs with atopic dermatitis: a randomized, blinded, placebo-controlled trial. J Vet Pharmacol Ther 2010;33:573-582.
24. Tumulty JW, Broussard JD, Steiner JM, et al. Clinical effects of short-term oral budesonide on the hypothalamic-pituitaryadrenal axis in dogs with inflammatory bowel disease. J Am Anim Hosp Assoc 2004;40:120-123.
25. Deng P, Duan XT, Chen XY, et al. LC-MS/MS determination of budesonide in dog plasma. Yao Xue Xue Bao 2008;43:76-80.
26. Casamian-Sorrosal D, Willard MD, Murray JK, et al. Comparison of histopathologic findings in biopsies from the duodenum and ileum of dogs with enteropathy. J Vet Intern Med 2010;24:80-83.
27. Seidegård J, Nyberg L, Borgå O. Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole. Eur J Pharm Sci 2008;35:264-270.
28. Szefler SJ. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J Allergy Clin Immunol 1999;104:175-183.
29. Jendbro M, Johansson CJ, Strandberg P, et al. Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. Drug Metab Dispos 2001;29:769-776.
30. Allenspach K, Bergman PJ, Sauter S, et al. P-glycoprotein expression in lamina propria lymphocytes of duodenal biopsy samples in dogs with chronic idiopathic enteropathies. J Comp Pathol 2006;134:1-7.
31. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996;110:45-51.